Google, Biogen team up on MS research: report

Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec ($BIIB) will team up with online overlord Google ($GOOG) to sift through a mountain of data on the topic, according to a report from Bloomberg. The big goal for Biogen, a leader in the field, is to get a better idea of why some patients see the disease progress so much faster than others. And if it's successful, they could get information that will help guide prescribing existing drugs as well as develop new ones. This is Google X labs' second big pharma collaboration. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.